Skip to content
Glycovax Pharma Logo
  • About
  • Technology
  • Contact
  • FR

Glycovax-NRC-Pa-Vaccine-NR-EN-03-06-25

By Claude Dagenais | March 6, 2025

Glycovax Pharma partners with NRC and Université de Montréal to fight Pseudomonas aeruginosa (Pa)

Search

Recent Posts

  • Glycovax Pharma commercializes an outstanding CRM197
  • Glycovax Pharma Joins Forces with NRC and Université de Montréal to Combat Pseudomonas aeruginosa
  • Glycovax Pharma launches a highly performant SLA Adjuvant
  • Glycovax Pharma develops a vaccine to fight Pa-related infections

Recent Comments

    Archives

    • March 2025
    • February 2025

    Categories

    • News
    • Press releases

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact us

    info@glycovax.com

    info@glycovax.com

    1 450 688-7760

    1 450 688-7760

    424, Guy street, suite 202 Montréal (Quebec) Canada H3J 1S6

    Headquarters
    424, Guy street, suite 202
    Montréal (Quebec) Canada H3J 1S6

    500, Cartier boulevard, suite 115 Laval (Quebec) Canada H7V 5B7

    Laboratories
    500, Cartier boulevard, suite 115
    Laval (Quebec) Canada H7V 5B7

    Resources

    About Glycovax Pharma

    Technology

    Contact Us

    Privacy Policy

    Facebook Glycovax LinkedIn Glycovax Pharma
    Glycovax Pharma Logo vertical reverse

    About Glycovax

    Glycovax Pharma develops innovative carbohydrate-based vaccines to address critical health needs. We aim to deliver safe and effective solutions to empower vaccine developers as well as protect communities worldwide by fostering scientific excellence, collaboration and leveraging cutting-edge technology.

    Humains : solutions Web créatives

    © 2025 Glycovax Pharma. All Rights Reserved.